Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence

Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies

“…SLPI has been tested as an ovarian cancer biomarker previously, with reasonable accuracy for differential diagnosis of malignant disease 31. In another case‐control study, serum SLPI showed stage‐specific elevation, although was not selected for inclusion in the multimarker models that were tested 32. Our data support these previous findings and suggest that SLPI may have some utility as a serum marker for ovarian cancer, although combining SLPI with CA125 did not improve on CA125 as a single marker.…”

Modification of Cutoff Values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for Ovarian Cancer Detection in Jakarta, Indonesia

“…Another study also showed that Indian and Malay healthy women had a different HE4 level (Mokhtar, 2012). Havrilesky, et al and Gorp et al showed that a same cutoff values might results in different diagnostic values on a study population with different stages of disease (Havrilesky, 2008;Van Gorp, 2011). This finding could also be seen in this study, in figure 1, where the AUC of every biomarkers and scorings are different in early and advance stage of EOC.…”

“…Since there is no screening method, ovarian cancer is often diagnosed when the patients already have had complaints, or in advanced stages. This condition brings difficulty and complexity of therapy that consequently leads to poorer prognosis (Havrilesky et al, 2008).…”

Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses

“…The poor sensitivity and specificity of CA125 have stimulated the search for a more reliable biomarker sought to improve the diagnostic accuracy of identifying malignancy in women with a pelvic mass (Havrilesky et al, 2008). Among a wide spectrum of serum biomarkers proposed to aid in the diagnosis of women presenting with a suspicious pelvic mass, human epididymis protein 4 (HE4), has been introduced as a novel biomarker for ovarian cancer diagnosis (Hellström et al, 2003;Su et al, 2013).…”